Cargando…

Differential Effects of Acetylcholinesterase Inhibitors on Clinical Responses and Cerebral Blood Flow Changes in Patients with Alzheimer's Disease: A 12-Month, Randomized, and Open-Label Trial

BACKGROUND/AIMS: The present study evaluated the differences in treatment outcomes and brain perfusion changes among 3 types of acetylcholinesterase inhibitors (AchEIs, i.e. donepezil, rivastigmine, and galantamine). METHODS: This was a prospective, longitudinal, randomized, open-label, 3-arm (donep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimizu, Soichiro, Kanetaka, Hidekazu, Hirose, Daisuke, Sakurai, Hirohumi, Hanyu, Haruo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439833/ https://www.ncbi.nlm.nih.gov/pubmed/25999980 http://dx.doi.org/10.1159/000375527

Ejemplares similares

Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer’s disease
por: Shimizu, Soichiro, et al.
Publicado: (2015)

A Longitudinal SPECT Study of Different Patterns of Regional Cerebral Blood Flow in Alzheimer's Disease with or without Diabetes
por: Hirao, Kentaro, et al.
Publicado: (2011)

Differentiating Mild Cognitive Impairment, Alzheimer's Disease, and Dementia With Lewy Bodies Using Cingulate Island Sign on Perfusion IMP-SPECT
por: Kanetaka, Hidekazu, et al.
Publicado: (2020)

Sarcopenia and Muscle Functions at Various Stages of Alzheimer Disease
por: Ogawa, Yusuke, et al.
Publicado: (2018)

Associations of depressive symptoms with white matter abnormalities and regional cerebral blood flow in patients with amnestic mild cognitive impairment
por: Hirao, Kentaro, et al.
Publicado: (2022)

Efficacy of Olfactory and Pareidolia Tests Compared With That of Indicative Biomarkers in Diagnosis of Dementia With Lewy Bodies
por: Inagawa, Yuta, et al.
Publicado: (2020)

Cerebrospinal fluid analysis in individuals with diabetes-related dementia
por: Kanetaka, Hidekazu, et al.
Publicado: (2017)

Association between clinical symptoms and post‐mortem neuropathology in dementia with Lewy bodies
por: Kaneko, Yoshitsugu, et al.
Publicado: (2020)

Association of regional white matter hyperintensity volumes with cognitive dysfunction and vascular risk factors in patients with amnestic mild cognitive impairment
por: Hirao, Kentaro, et al.
Publicado: (2021)

Association of White Matter Hyperintensity Progression with Cognitive Decline in Patients with Amnestic Mild Cognitive Impairment
por: Hirao, Kentaro, et al.
Publicado: (2021)

Association of serum cystatin C with white matter abnormalities in patients with amnestic mild cognitive impairment
por: Hirao, Kentaro, et al.
Publicado: (2019)

Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases
por: Shimizu, Soichiro, et al.
Publicado: (2018)

Altered Levels of Acetylcholinesterase in Alzheimer Plasma
por: García-Ayllón, María-Salud, et al.
Publicado: (2010)

New Acetylcholinesterase Inhibitors for Alzheimer's Disease
por: Mehta, Mona, et al.
Publicado: (2012)

N-Acetylcholinesterase-Induced Apoptosis in Alzheimer's Disease
por: Toiber, Debra, et al.
Publicado: (2008)

Language impairment in Alzheimer’s disease and benefits of acetylcholinesterase inhibitors
por: Ferris, Steven H, et al.
Publicado: (2013)

The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease
por: Vecchio, Immacolata, et al.
Publicado: (2021)

Flow-Through Acetylcholinesterase Sensor with Replaceable Enzyme Reactor
por: Ivanov, Alexey, et al.
Publicado: (2022)

Cerebral blood flow in Alzheimer’s disease
por: Roher, Alex E, et al.
Publicado: (2012)

Evaluation of cerebral blood flow in older patients with status epilepticus using arterial spin labeling
por: Ueno, Tatsuya, et al.
Publicado: (2018)

Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study
por: Mattingly, Greg W., et al.
Publicado: (2020)

Heterologous Amyloid Seeding: Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease
por: Jean, Létitia, et al.
Publicado: (2007)

Acetylcholinesterase Inhibition of Diversely Functionalized Quinolinones for Alzheimer’s Disease Therapy
por: Bautista-Aguilera, Óscar M., et al.
Publicado: (2020)

Molecular docking analysis of acetylcholinesterase inhibitors for Alzheimer's disease management
por: Hakeem, Israa J
Publicado: (2023)

Effect of Acetylcholinesterase Inhibitors on Cerebral Perfusion and Cognition: A Systematic Review
por: Moyaert, Paulien, et al.
Publicado: (2023)

Differentiation Between Dementia With Lewy Bodies And Alzheimer’s Disease Using Voxel-Based Morphometry Of Structural MRI: A Multicenter Study
por: Matsuda, Hiroshi, et al.
Publicado: (2019)

12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial
por: Han, Bingfeng, et al.
Publicado: (2021)

FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer’s disease
por: Paroni, Giulia, et al.
Publicado: (2014)

Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer’s Disease
por: Son, Minky, et al.
Publicado: (2019)

Inhibiting Acetylcholinesterase to Activate Pleiotropic Prodrugs with Therapeutic Interest in Alzheimer’s Disease
por: Toublet, François-Xavier, et al.
Publicado: (2019)

Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy
por: dos Santos, Thaiane Coelho, et al.
Publicado: (2018)

Molecular interaction of human acetylcholinesterase with trans-tephrostachin and derivatives for Alzheimer's disease
por: Pitchai, Arjun, et al.
Publicado: (2020)

Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy
por: Arya, Ashwani, et al.
Publicado: (2021)

Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews
por: Moreta, Marta Pérez-Gómez, et al.
Publicado: (2021)

Proposing novel natural compounds against Alzheimer’s disease targeting acetylcholinesterase
por: Girgin, Münteha, et al.
Publicado: (2023)

Efficacy of Souvenaid(®) Combined with Acetylcholinesterase Inhibitors in the Treatment of Mild Alzheimer’s Disease
por: García-Alberca, José María, et al.
Publicado: (2023)

Juvéderm(®) Volbella™ in the perioral area: a 12-month prospective, multicenter, open-label study
por: Eccleston, David, et al.
Publicado: (2012)

Altered Cerebral Blood Flow in Alzheimer's Disease With Depression
por: Li, Runzhi, et al.
Publicado: (2021)

Regional Cerebral Blood Flow in Mild Cognitive Impairment and Alzheimer's Disease Measured with Arterial Spin Labeling Magnetic Resonance Imaging
por: Sierra-Marcos, Alba
Publicado: (2017)

Acetylcholinesterase inhibitor modifications: a promising strategy to delay the progression of Alzheimer's disease
por: Bhattacharya, Soumee, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ib1p2gsiodabqqrvmbk2b8m2gq